Morphosys To Present New Phase 3 MANIFEST-2 Data On Pelabresib In Myelofibrosis In Oral Presentation At 2024 ASCO Annual Meeting menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
MorphoSys AG: MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
EQS-News: MorphoSys AG / Key word: Annual Report
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
13.03.2024 / 21:01.
Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize.